Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States (U....

Related Keywords

United States ,Massachusetts ,Washington ,Athlone ,Westmeath ,Ireland ,Ohio ,Waltham ,Dublin ,American ,Michael Pollock ,Todd Nichols ,Marisa Borgasano ,Sandy Coombs ,Eli Lilly ,American Psychiatric Association ,Nasdaq ,Alkermes Inc ,Alkerme Patient Assistance Program ,Alkermes ,Eli Lilly Company ,Drug Administration ,Clinical Development Program ,Patient Assistance Program ,National Comorbidity Survey Replication ,Savings Program ,Exchange Commission ,Bipolar Support Alliance ,Alkermes Pharma Ireland ,Multichannel News Release ,Chief Commercial Officer ,Alkerme Medical Information ,Alkermes Medical Information ,Negative Syndrome Scale ,Prescribing Information ,Adverse Reactions ,Elderly Patients ,Dementia Related Psychosis ,Boxed Warning ,Severe Opioid Withdrawal ,Physiologically Dependent ,Life Threatening Opioid Overdose ,Malignant Syndrome ,Systemic Symptoms ,Motor Impairment ,Temperature Dysregulation ,Combination Treatment ,Mixed Episodes ,Private Securities Litigation Reform Act ,Annual Report ,Alkermes Pharma Ireland Limited ,Adult Patients With ,Acute Exacerbation ,Outcomes From ,Olanzapine Combined With Samidorphan ,Weight Gain ,Week Phase ,Tolerability Results ,Combination Olanzapine ,American Psychiatric ,Schizophrenia Spectrum ,Statistical Manual ,American Psychiatric Publishing ,Month Prevalence ,Bipolar Spectrum Disorder ,National Comorbidity Survey ,Arch Gen Psychiatry ,Alkermes Plc ,